Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype

Neuropsychopharmacology. 2009 Aug;34(9):2156-66. doi: 10.1038/npp.2009.41. Epub 2009 Apr 29.

Abstract

Alterations in muscarinic acetylcholine receptor (CHRM) populations have been implicated in the pathology of schizophrenia. Here we have assessed whether the receptor function of the M(1) subtype (CHRM1) is altered in a sub-population of patients with schizophrenia, defined by marked (60-80%) reductions in cortical [3H]-pirenzepine (PZP) binding, and termed 'muscarinic receptor-deficit schizophrenia' (MRDS). Using a [35S]-GTPgammaS-Galpha(q/11) immunocapture method we have assessed whether CHRM1 signalling in human cortex (Brodmann area 9 (BA9)) is altered in post mortem tissue from a MRDS group compared with a subgroup of patients with schizophrenia displaying normal PZP binding, and controls with no known history of psychiatric or neurological disorders. The CHRM agonist (oxotremorine-M) and a CHRM1-selective agonist (AC-42) increased Galpha(q/11)-[35S]-GTPgammaS binding, with AC-42 producing responses that were approximately 50% of those maximally evoked by the full agonist, oxotremorine-M, in control and subgroups of patients with schizophrenia. However, the potency of oxotremorine-M to stimulate Galpha(q/11)-[35S]-GTPgammaS binding was significantly decreased in the MRDS group (pEC(50) (M)=5.69+/-0.16) compared with the control group (6.17+/-0.10) and the non-MRDS group (6.05+/-0.07). The levels of Galpha(q/11) protein present in BA9 did not vary with diagnosis. Maximal oxotremorine-M-stimulated Galpha(q/11)-[35S]-GTPgammaS binding in BA9 membranes was significantly increased in the MRDS group compared with the control group. Similar, though non-statistically significant, trends were observed for AC-42. These data provide evidence that both orthosterically and allosterically acting CHRM agonists can stimulate a receptor-driven functional response ([35S]-GTPgammaS binding to Galpha(q/11)) in membranes prepared from post mortem human dorsolateral prefrontal cortex of patients with schizophrenia and controls . Furthermore, in a subgroup of patients with schizophrenia displaying markedly decreased PZP binding (MRDS) we have shown that although agonist potency may decrease, the efficacy of CHRM1-Galpha(q/11) coupling increases, suggesting an adaptative change in receptor-G protein coupling efficiency in this endophenotype of patients with schizophrenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Female
  • GTP-Binding Protein alpha Subunits, Gq-G11 / metabolism
  • Guanosine 5'-O-(3-Thiotriphosphate) / metabolism
  • Humans
  • Male
  • Middle Aged
  • Muscarinic Agonists / pharmacology
  • Muscarinic Antagonists / pharmacology
  • Oxotremorine / analogs & derivatives
  • Oxotremorine / pharmacology
  • Phenotype
  • Piperidines / pharmacology
  • Pirenzepine / pharmacology
  • Prefrontal Cortex / drug effects
  • Prefrontal Cortex / metabolism*
  • Protein Binding / drug effects
  • Receptor, Muscarinic M1
  • Receptors, Muscarinic / metabolism*
  • Schizophrenia / drug therapy
  • Schizophrenia / metabolism*
  • Sulfur Radioisotopes
  • Tritium
  • Young Adult

Substances

  • 4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride
  • CHRM1 protein, human
  • Muscarinic Agonists
  • Muscarinic Antagonists
  • Piperidines
  • Receptor, Muscarinic M1
  • Receptors, Muscarinic
  • Sulfur Radioisotopes
  • Tritium
  • Guanosine 5'-O-(3-Thiotriphosphate)
  • Pirenzepine
  • Oxotremorine
  • oxotremorine M
  • GTP-Binding Protein alpha Subunits, Gq-G11